Literature DB >> 17960339

Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP).

Dirk Rades1, Guenther Bohlen, Radka Lohynska, Theo Veninga, Lukas J A Stalpers, Steven E Schild, Juergen Dunst.   

Abstract

BACKGROUND: Whole brain radiotherapy (WBRT) is the most common treatment for brain metastases. Survival of patients with cancer of unknown primary (CUP) presenting with brain metastases is extremely poor. A radiation program with a short overall treatment time (short-course RT) would be preferable to longer programs if it provides similar outcomes. This study compares short-course RT with 20 Gy in 5 fractions (5 x 4 Gy) given over 5 days to longer programs in CUP patients. PATIENTS AND METHODS: Data regarding 101 CUP patients who received either short course WBRT (n=34) with 5 x 4 Gy or long-course WBRT (n=67) with 10 x 3 Gy given over 2 weeks or 20 x 2 Gy given over 4 weeks for brain metastases were analyzed retrospectively. Six additional potential prognostic factors were investigated: age, gender, Karnofsky performance score (KPS), number of brain metastases, extracranial metastases, RPA-(Recursive Partitioning Analysis-)class.
RESULTS: On univariate analysis, the radiation program was not associated with survival (p=0.88) nor intracerebral control (p=0.36). Improved survival was associated with KPS >or= 70 (p<0.001), absence of extracranial metastases (p<0.001), and RPA-class 1 (p<0.001). On multivariate analyses, KPS (risk ratio [RR]: 4.55; p<0.001), extracranial metastases (RR: 1.70; p=0.018), and RPA-class (RR: 2.86; p<0.001) maintained significance. On univariate analysis, KPS (p<0.001) and RPA-class (p<0.001) were significantly associated with intracerebral control. On multivariate analyses, KPS (RR: 2.72; p<0.001) and RPA-class (RR: 2.09; p<0.001) remained significant.
CONCLUSION: Short-course WBRT with 5 x 4 Gy provided similar intracerebral control and survival as longer programs for the treatment of brain metastases in CUP patients. 5 x 4 Gy appears preferable because it is more convenient for patients.

Entities:  

Mesh:

Year:  2007        PMID: 17960339     DOI: 10.1007/s00066-007-1763-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  12 in total

1.  MRI evaluation of the effects of whole brain radiotherapy on breast cancer brain metastasis.

Authors:  William Crowe; Lulu Wang; Zhongwei Zhang; Jasmina Varagic; J Daniel Bourland; Michael D Chan; Amyn A Habib; Dawen Zhao
Journal:  Int J Radiat Biol       Date:  2019-01-07       Impact factor: 2.694

Review 2.  Airway hydration and COPD.

Authors:  Arunava Ghosh; R C Boucher; Robert Tarran
Journal:  Cell Mol Life Sci       Date:  2015-06-12       Impact factor: 9.261

3.  Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies.

Authors:  C Nieder; N H Andratschke; H Geinitz; A L Grosu
Journal:  Strahlenther Onkol       Date:  2012-04-26       Impact factor: 3.621

4.  Outcome of moderately dosed radiosurgery for limited brain metastases. Report of a single-center experience.

Authors:  Johanna Meisner; Andreas Meyer; Bernd Polivka; Johann H Karstens; Michael Bremer
Journal:  Strahlenther Onkol       Date:  2010-01-26       Impact factor: 3.621

Review 5.  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Laurie E Gaspar; Minesh P Mehta; Roy A Patchell; Stuart H Burri; Paula D Robinson; Rachel E Morris; Mario Ammirati; David W Andrews; Anthony L Asher; Charles S Cobbs; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

6.  Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases.

Authors:  Dirk Rades; Jan-Dirk Kueter; Dagmar Hornung; Theo Veninga; Patrick Hanssens; Steven E Schild; Juergen Dunst
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

7.  Hypofractionated reirradiation for recurrent malignant glioma.

Authors:  Guido Henke; Frank Paulsen; Joachim P Steinbach; Ute Ganswindt; Hana Isijanov; Rolf-Dieter Kortmann; Michael Bamberg; Claus Belka
Journal:  Strahlenther Onkol       Date:  2009-02-25       Impact factor: 3.621

8.  Effects of radiotherapy for brain metastases on quality of life (QoL). Prospective pilot study of the DEGRO QoL working party.

Authors:  Diana Steinmann; Christof Schäfer; Birgitt van Oorschot; Hans-Joachim Wypior; Frank Bruns; Tobias Bölling; Susanne Sehlen; Juliane Hagg; Anja Bayerl; Hans Geinitz; Matthias Hipp; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2009-03       Impact factor: 3.621

Review 9.  From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC.

Authors:  Maria Protopapa; Vassilis Kouloulias; Styliani Nikoloudi; Christos Papadimitriou; Giannis Gogalis; Anna Zygogianni
Journal:  J Oncol       Date:  2019-02-03       Impact factor: 4.375

Review 10.  Prognostic indices for brain metastases--usefulness and challenges.

Authors:  Carsten Nieder; Minesh P Mehta
Journal:  Radiat Oncol       Date:  2009-03-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.